Logo
Gonadorelin 10mg

Gonadorelin 10mg

Gonadorelin

Peptide hormone / research peptide
  • Sold as a research peptide rather than an MHRA Authorised medicinal product; therefore it does not carry a UK marketing authorisation for therapeutic use.
  • Any GMP, ISO or other quality certifications applicable to the manufacturing site are not explicitly disclosed by the seller and should be confirmed directly with the manufacturer if required for institutional quality Assurance purposes.
  • Clinical use of gonadorelin in the UK and EU is restricted to specific licensed medicinal products that comply with MHRA or EMA authorisation, each with its own Summary of Product Characteristics; this research vial is outside that regulatory framework.
Synthetic gonadotropin-releasing hormone (GnRH) decapeptide, 10 mg vial (research use)

Description

Gonadorelin 10mg is a synthetic form of gonadotropin-releasing hormone (GnRH), a decapeptide produced naturally by the hypothalamus that stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In licensed medicinal products, gonadorelin (or its acetate/hydrochloride salts) is used primarily as a diagnostic agent to assess pituitary gonadotroph function and, in specific formulations, for the treatment of certain forms of infertility and hypogonadism. The 10 mg vial format as supplied by Derma Filler Ltd is presented as a high-purity peptide intended for laboratory and research use, typically as a lyophilised powder in a glass vial, and is not an authorised medicinal presentation for human or veterinary treatment.

Bnefits

  • Synthetic analogue of endogenous gonadotropin-releasing hormone (GnRH), allowing controlled study of the hypothalamic–pituitary–gonadal axis in experimental settings.
  • High peptide content (10 mg per vial) suitable for a range of in vitro or pre-clinical research applications when appropriately reconstituted and handled in a laboratory environment.
  • Mimics the physiological GnRH signal at pituitary gonadotroph cells, leading to LH and FSH release in biological models, enabling investigation of reproductive endocrinology and hormone regulation.
  • Clinically, gonadorelin has established use (in licensed dosage forms) as a diagnostic agent for pituitary function and in selected cases for the treatment of infertility and hypogonadism, providing a well-characterised pharmacological profile for reference.
  • Ongoing research has examined potential roles of GnRH analogues, including gonadorelin, in hormone-sensitive conditions such as breast and prostate cancer, as well as investigational work in neurodegenerative diseases such as Alzheimer’s, making it of interest in translational research.
  • Supplied as a discrete vial that can be incorporated into controlled laboratory protocols under institutional biosafety and ethical frameworks.

Indications

  • Sold and supplied as a research peptide for laboratory use only (e.g., in vitro assays, receptor-binding studies, cell culture or animal models conducted under appropriate ethical approval and regulatory oversight).
  • Not indicated or authorised for direct administration to humans or animals in this 10 mg research-vial presentation.
  • For background medical context only (relating to licensed medicinal products, not this vial): gonadorelin in approved formulations is used as a diagnostic agent to test pituitary gonadotroph function and, under specialist supervision, in certain infertility and hypogonadism settings; such use must follow the specific licensed product’s prescribing information and regulatory approvals rather than any research-only vial.

Composition

  • Active peptide: Gonadorelin (synthetic gonadotropin-releasing hormone, GnRH), a decapeptide with the sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, 10 mg per vial.
  • Salt form: commonly supplied as gonadorelin acetate or gonadorelin hydrochloride in medicinal products; the exact salt or base form for this research vial is not explicitly stated by the seller.
  • Physical form: typically provided as a lyophilised (freeze-dried) or powder peptide in a sterile or clean glass vial suitable for laboratory reconstitution (e.g., with bacteriostatic water or buffered solution) according to institutional protocols.
  • Potential excipients (not detailed by the seller): some commercial gonadorelin medicinal products use excipients such as mannitol, sodium chloride and acids for pH adjustment; the exact excipient profile of this research vial is not disclosed and should be confirmed with the peptide’s certificate of analysis or accompanying technical data sheet where available.

Formulation

  • High-purity synthetic peptide formulation containing 10 mg gonadorelin per vial, usually as a lyophilised or powder form for reconstitution.
  • Designed for stability as a dry peptide under recommended storage conditions, with reconstitution performed immediately prior to experimental use as per laboratory procedures.
  • Non-buffered or minimally buffered peptide presentation (exact formulation not disclosed) intended to be combined with a suitable diluent in the laboratory.
  • Non-pyrogen-tested status for clinical injection cannot be assumed; this format is marketed primarily as a research chemical, not as a finished pharmaceutical injection for patients.

Packaging

  • Single 10 mg glass vial containing synthetic gonadorelin peptide (research presentation).
  • Vial closed with a rubber stopper and sealed with a flip-off cap according to typical peptide-vial configurations (exact closure type may vary by batch and manufacturer).
  • Supplied in secondary packaging (e.g., small carton or protective sleeve) bearing product designation and basic handling information as provided by the seller.
  • Bulk or multi-vial packs may be offered by some suppliers, but the Derma Filler Ltd listing referenced here specifically describes the 10 mg vial as an individual unit.
  • No patient information leaflet or medicinal product labelling is provided with this research vial; it is not packaged as a prescription medicine.

Usage

  • This Gonadorelin 10mg vial is marketed as a research peptide and is not an authorised medicinal product; it must not be used for self-administration or for treating humans or animals.
  • Laboratories intending to use this peptide should follow their institution’s standard operating procedures for handling peptides, including reconstitution, dilution, storage of working solutions and safe disposal.
  • Reconstitution should be performed in a suitable sterile environment using an appropriate diluent and aseptic technique, by trained laboratory personnel; the exact solvent, final concentration and experimental protocol are determined by the specific study design.
  • Researchers must consult and rely on primary literature, regulatory documents and institutional biosafety guidance for experimental dosing and administration in cell or animal models; such protocols fall under research governance and ethical approval, not consumer or patient guidance.
  • Clinical use of gonadorelin in humans should only occur using licensed medicinal products (e.g. specific gonadorelin injections authorised by regulatory agencies) and strictly under the direction of a qualified prescriber following the official Summary of Product Characteristics or equivalent prescribing information.
  • Do not inject, ingest or otherwise administer the contents of this research vial to any person or animal outside a regulated research protocol that explicitly permits such use and complies with all applicable laws and approvals.

Contraindications

  • This 10 mg vial is not authorised for human or veterinary treatment; any clinical contraindications apply to licensed gonadorelin medicinal products rather than this research presentation.
  • From a safety and governance standpoint, use is contraindicated outside appropriately approved laboratory or experimental settings.
  • For informational context regarding licensed medicinal forms of gonadorelin: contraindications commonly include known hypersensitivity to gonadorelin or any excipient; pregnancy and breastfeeding (except where a specialist explicitly decides otherwise); and situations where stimulation of the hypothalamic–pituitary–gonadal axis may be harmful (e.g., certain hormone-sensitive tumours) unless managed by an experienced clinician.
  • Individuals or organisations lacking appropriate regulatory, ethical or biosafety approvals should not handle or use research-grade gonadorelin in experimental work involving animals or human tissues.

Adverse Effects

  • No direct adverse-effect profile can be assigned to this research vial in the absence of authorised clinical use; any handling-related risks are primarily occupational (e.g., accidental exposure) and should be managed via laboratory safety procedures.
  • For background on licensed medicinal gonadorelin products: commonly reported adverse effects include transient flushing, headache, abdominal discomfort, nausea, dizziness and injection-site reactions (e.g., pain, redness, swelling).
  • In some clinical contexts, GnRH agonists can provoke a transient increase ("flare") in sex hormone levels, which may temporarily worsen hormone-dependent conditions (e.g., certain breast or prostate cancers) before downregulation; such effects and their management pertain to specific prescribed regimens, not to this research vial.
  • Rare but more serious adverse events associated with clinical GnRH analogue use can include hypersensitivity reactions, including anaphylaxis, and, depending on indication and regimen, ovarian hyperstimulation or thromboembolic events; these are managed within specialist care settings.
  • Laboratory personnel should avoid inhalation of powders, contact with skin or eyes and accidental injection; any accidental exposure should be handled according to institutional health and safety policies.

Storage Conditions

  • Store the vial in accordance with the conditions specified by the supplier on the product label or technical data sheet; peptides of this type are commonly stored refrigerated (e.g., 2–8 °C) in a dry place, protected from light.
  • Keep the vial in its original packaging until use to protect it from moisture and contamination.
  • Avoid repeated freeze–thaw cycles of reconstituted solutions; prepare aliquots if long-term experimental storage is necessary and only if validated by internal stability data.
  • Ensure that storage is secure and access is restricted to authorised laboratory personnel.
  • Do not use the product past its stated expiry date or if there is evidence of compromised integrity (e.g., damaged vial, discoloured contents).
  • Dispose of unused material and waste according to local regulations and institutional policies for chemical and biological laboratory waste.

Duration

Not applicable for the research-vial product in a therapeutic sense. In clinical practice with licensed gonadorelin medicines, treatment duration and diagnostic protocols vary widely depending on indication (e.g., single-dose diagnostic testing vs. controlled ovulation-induction regimens) and must be determined by a specialist using approved prescribing information; such details do not apply directly to this research-only 10 mg vial.

Onset

Not applicable for non-clinical research use in humans. Pharmacologically, when gonadorelin is administered as a licensed medicine, it acts rapidly on pituitary gonadotrophs to stimulate LH and FSH release, with measurable hormonal responses typically occurring within minutes; however, timing and clinical effect profiles are specific to dose, route and product and should be taken from the official information for the licensed medicinal product, not inferred from this research vial.

Browse more Peptide hormone / research peptide

Top Treatments

Top Cities in the UK